Management of aplastic anemia: The role of systematic reviews and meta-analyses

Acta Haematologica

Volumn 125, Issue 1-2, 2010, Pages 47-54

  Gafter Gvili, Anat ^a,b   Ram, Ron ^a,b   Raanani, Pia ^a,b   Shpilberg, Ofer ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allogeneic transplantation; Antithymocyte globulin; Aplastic anemia; Cyclosporine; Hematopoietic growth factors; Meta analysis; Systematic review

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ERYTHROPOIETIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; METHOTREXATE; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; DRUG INDICATION; DRUG USE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC);

ANEMIA, APLASTIC; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS AS TOPIC; REVIEW LITERATURE AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650352894     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318893     Document Type: Article

References (40)

1. Brodsky RA: Biology and management of acquired severe aplastic anemia. Curr Opin Oncol 1998; 10: 95-99.
2. Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, Laporte JR: Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008; 93: 518-523.
3. Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, Young NS: The epidemiology of aplastic anemia in Thailand. Blood 2006; 107: 1299-1307.
4. Young NS, Calado RT, Scheinberg P: Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.
5. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, Santos G, Gordon-Smith EC, Storb R: A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504-514.
6. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, Congiu M, De Planque MM, Ernst P, McCann S: Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70: 177-182.
7. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, Ribaud P, Devergie A, Traineau R, Gluckman E, Socié G: Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490-2497. (Pubitemid 38392998)
8. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA: Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70.
9. Harbour R, Miller J: A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-336.
10. Crowther MA, Cook DJ: Trials and tribulations of systematic reviews and meta-analyses. Hematology Am Soc Hematol Educ Program 2007, pp 493-497.
11. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM, Storb R: Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63-70.
12. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, Van Lint MT, Tichelli A, McCann S, Marsh J, Ljungman P, Hows J, Marin P, Schrezenmeier H: Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - the European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80.
13. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, Chauncey T, Clift RA, Deeg HJ, Doney KC, Flowers ME, Hansen JA, Martin PJ, Sanders JE, Sullivan KM, Witherspoon RP: Longterm follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89: 3890-3891.
14. Anasetti C, Doney KC, Storb R, Meyers JD, Farewell VT, Buckner CD, Appelbaum FR, Sullivan KM, Clift RA, Deeg HJ, Fefer A, Martin PJ, Singer JW, Sanders JE, Stewart PS, Witherspoon RP, Thomas ED: Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty 'untransfused' patients. Ann Intern Med 1986; 104: 461-466.
15. Horowitz MM: Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000; 37: 30-42.
16. Armand P, Antin JH: Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007; 13: 505-516.
17. Peinemann F, Grouven U, Kroger N, Pittler M, Zschorlich B, Lange S: Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica 2009; 94: 1732-1742.
18. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socié G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A: Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999; 93: 2191-2195.
19. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, Bryant E, Clift R, Deeg HJ, Doney K, Flowers M, Hansen J, Martin P, Pepe M, Sale G, Sanders J, Singer J, Sullivan KM, Thomas ED, Witherspoon RP: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
20. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MM: Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585.
21. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, Prete A, Locasciulli A, Cesaro S, Passweg J, Severe Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplant (EBMT): Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA working party. Bone Marrow Transplant 2005; 36: 947-950.
22. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125. (Pubitemid 16041720)
23. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, Dallorso S, Di Bartolomeo P, Fagioli F, Locasciulli A, Lawler M, Bacigalupo A: Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLAidentical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
24. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O: Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009; 43: 643-653.
25. Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T, Muramatsu H, Morishima Y, Kodera Y: Tacrolimus/methotrexate versus cyclosporine/methotrexate as graft-versushost disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant 2009; 15: 1603-1608.
26. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, Camitta BM, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Schattenberg AV, Socié G, Eapen M: Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
27. Stem Cell Trialists' Collaborative Group: Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
28. Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B: Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1415-1421.
29. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, Yabe H, Tsuchida M, Mugishima H, Ohara A, Morimoto A, Otsuka Y, Ohga S, Bessho F, Nakahata T, Tsukimoto I, Kojima S: Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111: 1054-1059.
30. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P, Ferster A: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO Blood 2000; 95: 1931-1934.
31. Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, Friedrich W, Ebell W, Borkhardt A, Bender-Goetze C: Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005; 106: 2102-2104.
32. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Führer M: Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92: 11-18.
33. Gafter-Gvili A, Ram R, Gurion R, Paul M, Yeshurun M, Raanani P, Shpilberg O: ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia - systematic review and meta-analysis. Acta Haematol 2008; 120: 237-243.
34. Vadhan-Raj S, Broxmeyer HE, Hittelman WN: Use of granulocyte-macrophage colony- stimulating factor in hematopoietic disorders: biology and nature of response. Semin Hematol 1992; 29: 4-13.
35. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A: Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group. Lancet 2001; 357: 43-44.
36. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, Shpilberg O, Raanani P: Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy - systematic review and meta-analysis. Haematologica 2009; 94: 712-719.
37. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Duehrsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR: Use of G-CSF in patients with severe aplastic anemia treated with ATG and cyclosporine increases neutrophils and decreases infection rates and hospitalization days but does not improve long-term outcome: results of a prospective, randomized clinical trial of the EBMT. Blood (ASH Annual Meeting Abstracts) 2009; 114: 496.
38. Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995.
39. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-5489.
40. Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L: Infection-control interventions for cancer patients after chemotherapy: a systematic review and metaanalysis. Lancet Infect Dis 2009; 9: 97-107.